

Cerebral ischaemia during haemodialysis - finding the signal in the noise

Clare MacEwen^{1,2}, Peter Watkinson^{2,3}, Lionel Tarassenko⁴, Christopher Pugh^{1,5}

1. Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK

2. Adult Intensive Care Unit, Oxford University Hospitals NHS Trust, Oxford, UK

3. Kadoorie Centre for Critical Care Research and Education, Kadoorie Centre for Critical Care Research and Education, Oxford University, Oxford, UK

4. Institute of Biomedical Engineering, Department of Engineering Science, Oxford University, Oxford, UK

5. Nuffield Department of Medicine, Oxford University, Oxford, UK

Corresponding author:

Dr Clare MacEwen, Oxford Kidney Unit,
Churchill Hospital, Oxford, OX3 7LJ

Tel +447799774764

Fax +441865617703

Email : clare.macewen@ouh.nhs.uk

Statement of competing financial interests

CM was previously funded by a National Institute of Health Research (NIHR) doctoral research fellowship. The research group additionally receives support and funding from the Oxford NIHR British Research Council (BRC). The authors have no conflict of interests to declare.

ABSTRACT

Haemodialysis patients have multiple risk factors for small vessel cerebrovascular disease and cognitive dysfunction. Haemodialysis itself may cause clinically significant neurological injury through repetitive cerebral ischaemia. However, supporting evidence to date consists of epidemiological associations, expert opinion, and small, single-centre studies of variable methodological quality. Isolating the impact of intra-dialytic haemodynamic instability from underlying renal and vascular disease on clinically relevant functional outcomes would require very large, controlled studies, given the heterogeneity and confounding comorbidities of the population, and the complex relationship between blood pressure and cerebral oxygen delivery. There has been an increase in complementary physiological studies looking directly at intra-dialytic cerebral oxygen balance, which have provided supporting evidence for the occurrence of cerebral ischaemia, often independently of haemodynamics. Data suggesting a relationship between these measures of oxygen balance and functional outcomes is only hypothesis-generating at this stage. We advocate the testing of interventions that aim to reduce intra-dialytic cerebral hypoxia (rather than hypotension) in sufficiently powered studies, followed by correlation with validated, longitudinal assessment of clinically relevant neurological damage.

ARTICLE

Advances in haemodialysis technology, monitoring and prescription over recent decades have enormously increased the safety and availability of the procedure. It currently serves as either destination treatment or a bridge to transplantation for approximately 384 per million population in the UK¹. Whilst life-sustaining, there is growing awareness that intermittent haemodialysis may carry significant physiological costs. In particular, the initiation of haemodialysis does not necessarily improve quality of life² and in other studies has been associated with a decline in cognitive function and performance status^{3,4}. Given the impact of cerebral function on quality of life, including functional independence and decision-making, this is a major concern.

There are many plausible mechanisms whereby haemodialysis may result in neurological injury. As an intermittent treatment, it involves fluctuations in fluid balance, electrolytes, uraemic toxins, and water-soluble medications. Osmotic stress, inflammation and microemboli are all recognised complications of the procedure⁵. Subclinical dialysis disequilibrium has been identified even in long term haemodialysis patients⁶. Blood exposure to filter membranes and dialysate impurities induces an inflammatory response, activating complement and coagulation cascades⁷. Levels of inflammatory markers correlate with cognitive performance in renal disease⁸. Much interest has focused on whether

intra-dialytic hypotension causes long term neurological injury through repetitive cerebral ischaemia, partly because it is most amenable to intervention⁵.

Elucidating the role of intra-dialytic hypotension is complex, as renal disease itself affects the brain through both metabolic and structural effects. Mechanisms include accumulation of uraemic toxins, endothelial dysfunction, vascular calcification, klotho deficiency and hypertension with associated dramatically accelerated small vessel cerebrovascular disease⁹. Cognitive impairment and white matter abnormalities are independently associated with renal impairment in a dose-related fashion^{10, 11, 12, 13}. Additionally, albuminuria is associated with cerebral white matter abnormalities and cognitive impairment independently of eGFR^{12, 14}. Conversely, some investigators have found that haemodialysis can be associated with improved cognitive performance, presumably by virtue of clearing uraemic toxins¹⁵. Given this background, it is extremely difficult to isolate the impact of ischaemic, osmotic and inflammatory insults derived from haemodialysis itself. How can we find the signal in the noise?

The data supporting haemodialysis-induced brain injury consist of epidemiological associations, expert opinion, and small often methodologically flawed studies^{5, 16, 17}. Injury to the brain can be assessed either by radiological methods, which provide largely structural information, or validated neurocognitive tests, which provide (arguably more important) functional information¹⁸. Some but not all observational studies have suggested that patients who undergo maintenance peritoneal rather than haemodialysis have a slower decline in cognitive function, or fewer abnormalities on brain magnetic resonance imaging (MRI)^{19, 20}. Increasing haemodialysis vintage has been associated with reductions in baseline cerebral blood flow, frontal lobe oxygenation and cognitive performance, as well as a greater burden of white matter abnormalities on MRI, particularly subtle changes on diffuser tensor imaging (DTI)^{21, 22, 23}. The potential for confounding in these studies is considerable, not least by time and treatment indication. Reliance on radiological measures of end organ damage is also problematic: many of the abnormalities detected are of uncertain significance. Some investigators have been able to demonstrate an association between DTI detected white matter changes and measures of executive function and processing speed, but most studies provide no clinical correlate^{22, 24}.

Studies looking at intra-dialytic haemodynamics might be expected to have more success. With sufficient patient numbers and haemodynamic data, blood pressure changes could be treated as an “intervention” in a pseudorandomised study. Both quality and quantity of data are vitally important as patients with

cardiovascular disease are likely to be prone to both intradialytic haemodynamic instability and cerebrovascular disease independently^{18,25}. Moreover accurate measurement of blood pressure on haemodialysis is challenging, further weakening any signal. Non-invasive arm-cuff blood pressure (NIBP), either sphygmomanometry or oscillometry, is intermittent and misses significant haemodynamic fluctuations. The popular volume clamp techniques (eg Finometer, Finapres Medical Systems, Enschede, The Netherlands) permit continuous non-invasive data collection, but are not available in routine clinical practice, and have never been validated in the end-stage renal failure population. Unfortunately, most published studies are small with sparse haemodynamic data, which is rarely screened for signal quality¹⁶. Many derive models and predictions using blood pressure from only one or two treatments, but haemodynamic status varies considerably between sessions and over time²⁶.

The evidence for an impact of intra-dialytic haemodynamics on brain structure and function can be briefly summarised. Frequent haemodialysis schedules almost certainly reduce haemodynamic and osmotic stress, but have not been found to impact on cognitive function^{3,27}. Two very different cross-sectional studies found no association between any domain of cognitive function and intra-dialytic haemodynamics^{28,29}. The larger study, in 383 patients, did not gather haemodynamic information, but used receipt of intra-dialytic fluid bolus in the week preceding cognitive testing as a surrogate for propensity to severe hypotension²⁹. In contrast, Wolgram et al. averaged NIBP indices from 12 consecutive sessions in a small cohort of 32 patients²⁸. The same 32 patients were reassessed after 12 months: there was no relationship between change in cognitive function and typical intra-dialytic haemodynamics, assessed from 15 sample sessions over the year³⁰.

Two longitudinal prospective studies looked at the association of intra-dialytic haemodynamics and progression of MRI-detected abnormalities, with the caveats regarding radiological endpoints discussed above. One found an association between progression of frontal lobe atrophy over 3 years and the total number of intra-dialytic hypotensive episodes recorded in clinical records over that period³¹. Another small single-centre trial found a relationship between dialysate temperature and white matter changes over 12 months, but this was not mediated by a difference in intra-dialytic hypotension, at least not in the two sessions monitored¹⁶. The authors found an association between white matter abnormalities and a non-standard and only partially controlled measure of variability in beat-to-beat mean arterial pressure (MAP) measured by a volume-clamp device¹⁶. Whilst longer term blood pressure variability has been well studied in chronic renal disease patients and appears to have prognostic significance³², beat-to-beat variability is a complex phenomenon

whose analysis requires rigorous methodological standards, and has not been robustly investigated in this population: it cannot yet be linked to either the haemodialysis procedure or to neurological outcomes³³⁻³⁷.

The failure to definitively link intra-dialytic haemodynamics to cerebral ischaemia may reflect the fact that blood pressure is only one factor determining cerebral oxygen delivery, which equals the product of cerebral blood flow and arterial oxygen content. Many factors beyond hypotension-induced reductions in cerebral blood flow may alter intra-dialytic cerebral oxygen delivery. Arterial oxygen content may be reduced by blood loss or intra-dialytic ventilation-perfusion mismatch (inflammation and neutrophil sequestration)³⁸. Cerebral vascular resistance may be altered by ultrafiltration-induced increases in blood viscosity and rising pCO₂ with bicarbonate loading³⁸. Regional autoregulation may preserve cerebral blood flow in the face of changing driving pressure, but this is not predictable³⁹. The lower threshold for cerebral autoregulation in haemodialysis patients is highly variable (95% confidence intervals 38.9 mmHg to 109.3 mmHg), and many lack autoregulation altogether⁴⁰. Most, but not all, transcranial Doppler studies report a decrease in middle cerebral artery blood flow velocity during haemodialysis^{41,42}. However, ultrafiltration-induced haemoconcentration will alter velocity independently of oxygen carrying capacity^{41,42}.

Even if there is reduced oxygen delivery due to intradialytic hypotension, anaemia, hypoxia or another cause, this does not necessarily lead to cellular ischaemia. Other factors such as the functional capillary density (distance from vessels to cells), oxygen dissociation curve (affected by pH, pCO₂ and temperature, all relevant to haemodialysis), cellular oxygen demand and mitochondrial health are important⁴³. A potentially cleaner method of detecting intra-dialytic cerebral ischaemia might therefore be to look directly at cerebral cellular oxygen balance during treatment, learning lessons from the neurocritical care literature⁴⁴.

Brain oxygenation reflects both oxygen delivery and consumption, and there are currently two measurement methods suitable for continuous monitoring at the bedside. Both assess local rather than global oxygen balance. The gold standard is direct, invasive measurement of oxygen tension in the brain parenchyma or CSF using specialised probes, with normal pO₂ ranging from 3.3 to 5.2 kPa^{44,45}. There is no scientific consensus on the extracellular pO₂ that first induces ischaemic stress in neurons, but PO₂ <1kPa is associated with neuronal death⁴⁴. This method is clearly not suitable for the haemodialysis outpatient. The alternative is near-infra-red spectroscopy (NIRS), which can

provide a continuous, non-invasive measurement of frontal lobe tissue oxygenation. Cerebral NIRS relies on the fact that infrared light can penetrate the skull: changes in haemoglobin oxygen saturation in the frontal cortex are estimated from the absorption of different wavelengths of near-infrared light by oxygenated and deoxygenated haemoglobin⁴⁶. Changes in cerebral saturations measured by spatially-resolved NIRS have generally, but not always, been shown to correlate well with changes in parenchymal brain tissue oxygenation⁴⁷⁻⁴⁹. A small body of literature supports a relationship between NIRS-detected cerebral desaturation and hard patient outcomes in other populations⁵⁰⁻⁵⁶. However a number of factors can reduce the accuracy of the signal and there is no consensus on what level of desaturation is harmful⁴⁶.

There are few studies investigating cerebral NIRS during haemodialysis; most have looked at very small numbers of sessions with no evaluation of neurological outcomes^{57,58}. However, our own group has found an association between decline in executive cognitive function over 12 months and typical exposure to intra-dialytic cerebral ischaemia, defined by area under the curve below the cut-off of a relative 15% drop in NIRS-measured cerebral saturations⁴⁰. A strength of our study included the large amount of high quality raw physiological data gathered (635 monitored sessions in 58 patients, including continuous volume-clamp blood pressure, belt respiratory rate, ECG, pulse oximetry, relative blood volume and cerebral NIRS, with robust signal processing and quality control). However, the findings can only be considered hypothesis-generating due to small patient numbers. In addition, this definition of ischaemia, though based on previous literature, is arbitrary.

Even assuming that cerebral ischaemia is a consequence of haemodialysis, it is not necessarily preventable. We identified some patients who repeatedly developed asymptomatic cerebral desaturation shortly after initiation of dialysis, in the absence of changes in blood pressure, cardiac output (validated with ultrasound dilution), respiratory rate, peripheral saturations, haematocrit or autonomic balance (estimated by spectral analysis of heart rate variability) – i.e. in the absence of a clear change in cerebral oxygen delivery (unpublished data). If we trust the NIRS signal, it is possible (but entirely speculative) that acute inflammation, changes in pH and ionic environment or changes in temperature are altering the oxygen diffusion gradient or distance, or cellular oxygen demand. This is not easily modulated.

In conclusion, the question of whether the haemodialysis procedure itself has adverse neurological consequences, in particular cerebral ischaemia, is more complex than it first seems. The occurrence of harmful repetitive intra-dialytic cerebral ischaemia is supported by biological plausibility and a growing body of circumstantial evidence from complementary epidemiological and physiological

studies, but finding the true signal in such heterogeneous, imperfect data is not an easy task. We would advocate suitably powered multicentre randomised controlled trials, testing the effects of interventions that aim to reduce intra-dialytic cerebral hypoxia (rather than hypotension), followed by correlation with validated, robust, longitudinal assessment of clinically relevant neurological damage over a period of years.

In the meantime, it is reasonable for clinicians to focus on optimising factors likely to impact on intra-dialytic tissue oxygen delivery. We suggest increased monitoring to detect subclinical hypotension and hypoxia, with consideration of convective treatments, cooling, or supplemental oxygen in high risk patients. There is evidence that blood pressure should generally be maintained above MAP 60 mmHg⁴⁰ or systolic blood pressure (SBP) 90 mmHg⁵⁹, but targets should be individualised: where present, the lower limit of cerebral autoregulation can be estimated from baseline MAP in haemodialysis patients as in other populations^{40,60}. In addition, we believe it is important to screen all haemodialysis patients for cognitive impairment as part of routine care, and address non-dialytic risk factors such as depression, neurotropic medications and lack of physical activity⁶¹.

1. Renal-Association. Sixteenth Annual Report. *UK Renal Registry*. 2013.
2. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med*. 2010;363(7):609-619.
3. Kurella Tamura M, Vittinghoff E, Hsu CY, et al. Loss of executive function after dialysis initiation in adults with chronic kidney disease. *Kidney Int*. 2017;91(4):948-953.
4. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. *N Engl J Med*. 2009;361(16):1539-1547.
5. Madero M, Sarnak MJ. Does hemodialysis hurt the brain? *Semin Dial*. 2011;24(3):266-268.
6. Walters RJ, Fox NC, Crum WR, Taube D, Thomas DJ. Haemodialysis and cerebral oedema. *Nephron*. 2001;87(2):143-147.
7. Kurella Tamura M, Tam K, Vittinghoff E, et al. Inflammatory Markers and Risk for Cognitive Decline in Chronic Kidney Disease: The CRIC Study. *Kidney Int Rep*. 2017;2(2):192-200.
8. Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. *Cell Mol Immunol*. 2006;3(2):151-154.
9. Lau WL, Huisa BN, Fisher M. The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms. *Transl Stroke Res*. 2017;8(1):67-76.
10. Slinin Y, Paudel ML, Ishani A, et al. Kidney function and cognitive performance and decline in older men. *J Am Geriatr Soc*. 2008;56(11):2082-2088.

11. Kurella M, Chertow GM, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. *J Am Geriatr Soc.* 2004;52(11):1863-1869.
12. Weiner DE, Gaussoin SA, Nord J, et al. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). *Am J Kidney Dis.* 2017;70(3):357-367.
13. Weiner DE, Seliger SL. Cognitive and physical function in chronic kidney disease. *Curr Opin Nephrol Hypertens.* 2014;23(3):291-297.
14. Georgakis MK, Dimitriou NG, Karalexi MA, et al. Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis. *J Am Geriatr Soc.* 2017;65(6):1190-1198.
15. Schneider SM, Malecki AK, Müller K, et al. Effect of a single dialysis session on cognitive function in CKD5D patients: a prospective clinical study. *Nephrol Dial Transplant.* 2015;30(9):1551-1559.
16. Eldehni MT, Odudu A, McIntyre CW. Randomized Clinical Trial of Dialysate Cooling and Effects on Brain White Matter. *J Am Soc Nephrol.* 2014.
17. Wolfgram DF, Szabo A, Murray AM, Whittle J. Risk of dementia in peritoneal dialysis patients compared with hemodialysis patients. *Perit Dial Int.* 2015;35(2):189-198.
18. Weiner DE, Scott TM, Giang LM, et al. Cardiovascular disease and cognitive function in maintenance hemodialysis patients. *Am J Kidney Dis.* 2011;58(5):773-781.
19. Pi HC, Xu YF, Xu R, et al. Cognitive Impairment and Structural Neuroimaging Abnormalities Among Patients with Chronic Kidney Disease. *Kidney Blood Press Res.* 2016;41(6):986-996.
20. Iyasere O, Okai D, Brown E. Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making. *Clin Kidney J.* 2017;10(1):89-94.
21. Hsieh T-J, Chang J-M, Chuang H-Y, et al. End-stage renal disease: in vivo diffusion-tensor imaging of silent white matter damage. *Radiology.* 2009;252(2):518-525.
22. Zhang R, Liu K, Yang L, et al. Reduced white matter integrity and cognitive deficits in maintenance hemodialysis ESRD patients: a diffusion-tensor study. *Eur Radiol.* 2015;25(3):661-668.
23. Chou M-C, Hsieh T-J, Lin Y-L, et al. Widespread white matter alterations in patients with end-stage renal disease: a voxelwise diffusion tensor imaging study. *AJNR Am J Neuroradiol.* 2013;34(10):1945-1951.
24. Kong X, Wen J-q, Qi R-f, et al. Diffuse interstitial brain edema in patients with end-stage renal disease undergoing hemodialysis: a tract-based spatial statistics study. *Medicine (Baltimore).* 2014;93(28):e313.
25. Naganuma T, Takemoto Y, Shoji T, et al. Cerebral white matter hyperintensity predicts cardiovascular events in haemodialysis patients. *Nephrology (Carlton).* 2013;18(10):676-681.
26. Kuipers J, Usvyat LA, Oosterhuis JK, et al. Variability of predialytic, intradialytic, and postdialytic blood pressures in the course of a week: a study of Dutch and US maintenance hemodialysis patients. *Am J Kidney Dis.* 2013;62(4):779-788.
27. Kurella Tamura M, Unruh ML, Nissenson AR, et al. Effect of more frequent hemodialysis on cognitive function in the frequent hemodialysis network trials. *Am J Kidney Dis.* 2013;61(2):228-237.
28. Wolfgram DF, Sunio L, Vogt E, et al. Haemodynamics during dialysis and cognitive performance. *Nephrology (Carlton).* 2014;19(12):771-776.

29. Kurella Tamura M, Larive B, Unruh ML, et al. Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials. *Clin J Am Soc Nephrol*. 2010;5(8):1429-1438.
30. Wolfgram D, Vogt E, Jahn AL, et al. Hemodynamics During Dialysis and Changes in Cognitive Performance. *WMJ*. 2016;115(6):311-316.
31. Mizumasa T, Hirakata H, Yoshimitsu T, et al. Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients: a 3-year prospective study. *Nephron Clin Pract*. 2004;97(1):c23-30.
32. Flythe JE, Brunelli SM. Blood pressure variability among chronic dialysis patients: recent advances in knowledge. *Curr Opin Nephrol Hypertens*. 2015;24(2):163-169.
33. Parati G, Saul JP, Di Rienzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. *Hypertension*. 1995;25(6):1276-1286.
34. Wessel N, Bauernschmitt R, Wernicke D, Kurths J, Malberg H. Autonomic cardiac control in animal models of cardiovascular diseases. I. Methods of variability analysis. *Biomed Tech (Berl)*. 2007;52(1):43-49.
35. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Eur Heart J*. 1996;17(3):354-381.
36. Pinna GD, Maestri R, Mortara A. Estimation of arterial blood pressure variability by spectral analysis: comparison between Finapres and invasive measurements. *Physiol Meas*. 1996;17(3):147-169.
37. Sanderson JE, Yeung LY, Yeung DT, et al. Impact of changes in respiratory frequency and posture on power spectral analysis of heart rate and systolic blood pressure variability in normal subjects and patients with heart failure. *Clin Sci (Lond)*. 1996;91(1):35-43.
38. Campos I, Chan L, Zhang H, et al. Intradialytic Hypoxemia in Chronic Hemodialysis Patients. *Blood Purif*. 2016;41(1-3):177-187.
39. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. *Cerebrovasc Brain Metab Rev*. 1990;2(2):161-192.
40. MacEwen C, Sutherland S, Daly J, Pugh C, Tarassenko L. Relationship between Hypotension and Cerebral Ischemia during Hemodialysis. *J Am Soc Nephrol*. 2017;28(8):2511-2520.
41. Metry G, Spittle M, Rahmati S, et al. Online monitoring of cerebral hemodynamics during hemodialysis. *Am J Kidney Dis*. 2002;40(5):996-1004.
42. Stefanidis I, Bach R, Mertens PR, et al. Influence of hemodialysis on the mean blood flow velocity in the middle cerebral artery. *Clin Nephrol*. 2005;64(2):129-137.
43. Schober P, Schwarte LA. From system to organ to cell: oxygenation and perfusion measurement in anesthesia and critical care. *J Clin Monit Comput*. 2012;26(4):255-265.
44. De Georgia MA. Brain Tissue Oxygen Monitoring in Neurocritical Care. *J Intensive Care Med*. 2015;30(8):473-483.
45. Meixensberger J, Dings J, Kuhnigk H, Roosen K. Studies of tissue PO₂ in normal and pathological human brain cortex. *Acta Neurochir Suppl (Wien)*. 1993;59:58-63.
46. Bakker A, Smith B, Ainslie P, Smith K. Near-Infrared Spectroscopy. <http://www.intechopen.com/books/applied-aspects-of-ultrasonography-in-humans/near-infrared-spectroscopy.2014>.

47. Holzschuh M, Woertgen C, Metz C, Brawanski A. Dynamic changes of cerebral oxygenation measured by brain tissue oxygen pressure and near infrared spectroscopy. *Neurol Res.* 1997;19(3):246-248.
48. Brawanski A, Faltermeier R, Rothoerl RD, Woertgen C. Comparison of near-infrared spectroscopy and tissue p(O₂) time series in patients after severe head injury and aneurysmal subarachnoid hemorrhage. *J Cereb Blood Flow Metab.* 2002;22(5):605-611.
49. Leal-Noval SR, Cayuela A, Arellano-Orden V, et al. Invasive and noninvasive assessment of cerebral oxygenation in patients with severe traumatic brain injury. *Intensive Care Med.* 2010;36(8):1309-1317.
50. Cerebral oxygen desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. *Ann Thorac Surg.* 2009;87(1):36-44; discussion 44-35.
51. Tang L, Kazan R, Taddei R, Zaouter C, Cyr S, Hemmerling TM. Reduced cerebral oxygen saturation during thoracic surgery predicts early postoperative cognitive dysfunction. *Br J Anaesth.* 2012;108(4):623-629.
52. de Tournay-Jetté E, Dupuis G, Bherer L, Deschamps A, Cartier R, Denault A. The relationship between cerebral oxygen saturation changes and postoperative cognitive dysfunction in elderly patients after coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth.* 2011;25(1):95-104.
53. Suehiro K, Okutai R. Duration of cerebral desaturation time during single-lung ventilation correlates with mini mental state examination score. *J Anesth.* 2011;25(3):345-349.
54. Murkin JM, Adams SJ, Novick RJ, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. *Anesth Analg.* 2007;104(1):51-58.
55. Kazan R, Bracco D, Hemmerling TM. Reduced cerebral oxygen saturation measured by absolute cerebral oximetry during thoracic surgery correlates with postoperative complications. *Br J Anaesth.* 2009;103(6):811-816.
56. Ono M, Brady K, Easley RB, et al. Duration and magnitude of blood pressure below cerebral autoregulation threshold during cardiopulmonary bypass is associated with major morbidity and operative mortality. *J Thorac Cardiovasc Surg.* 2014;147(1):483-489.
57. Ookawara S, Ito K, Ueda Y, et al. Differences in tissue oxygenation and changes in total hemoglobin signal strength in the brain, liver, and lower-limb muscle during hemodialysis. *J Artif Organs.* 2017.
58. Ito K, Ookawara S, Ueda Y, et al. Changes in Cerebral Oxygenation Associated with Intradialytic Blood Transfusion in Patients with Severe Anemia Undergoing Hemodialysis. *Nephron Extra.* 2017;7(1):42-51.
59. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. *J Am Soc Nephrol.* 2015;26(3):724-734.
60. Drummond JC. The lower limit of autoregulation: time to revise our thinking? *Anesthesiology.* 1997;86(6):1431-1433.
61. Kurella Tamura M, Larive B, Unruh ML, et al. Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials. *Clin J Am Soc Nephrol.* 2010;5(8):1429-1438.